Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
J Neuroimmunol ; 320: 117-124, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29661540

ABSTRACT

Macrophage migration inhibitory factor (MIF) is a cytokine associated with tissue damage in multiple autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis. The role of MIF in multiple sclerosis (MS) and the contribution of its polymorphisms are unknown in our population. Therefore, we decided to investigate the genetic association of -794 CATT5-8 (rs5844572) and -173 G>C (rs755622) MIF polymorphisms with MS, clinical variables and MIF serum levels in the population of western Mexico. 230 MS patients diagnosed according to McDonald criteria and 248 control subjects (CS) were recruited for this study, both polymorphisms were genotyped by PCR and PCR-RFLP and MIF serum levels were measured by ELISA kit. Severity and progression of MS were evaluated by EDSS and MSSS scores, respectively. Genotypes carrying the 5 repeats alleles of -794 CATT5-8MIF polymorphism present higher MIF serum levels in comparison with no carriers, and the presence of 5,7 heterozygous genotype contribute to the increase of disease severity and damage progression in MS patients. Notably when we stratified by sex, an effect of risk alleles (7 repeats and -173*C) of both MIF polymorphisms on EDSS and MSSS scores on males was found (p < 0.01). This study suggests that polymorphic alleles of MIF polymorphisms could act as sex-specific disease modifiers that increase the severity and progression of MS in male Mexican-Mestizo western population.


Subject(s)
Genetic Predisposition to Disease/genetics , Intramolecular Oxidoreductases/genetics , Macrophage Migration-Inhibitory Factors/genetics , Multiple Sclerosis/genetics , Sex Characteristics , Adult , Disease Progression , Female , Genotype , Humans , Male , Mexico , Middle Aged , Polymorphism, Single Nucleotide
3.
Neurologia ; 29(4): 200-9, 2014 May.
Article in English, Spanish | MEDLINE | ID: mdl-24021783

ABSTRACT

INTRODUCTION: Information regarding hospital arrival times after acute ischaemic stroke (AIS) has mainly been gathered from countries with specialised stroke units. Little data from emerging nations is available. We aim to identify factors associated with achieving hospital arrival times of less than 1, 3, and 6 hours, and analyse how arrival times are related to functional outcomes after AIS. METHODS: We analysed data from patients with AIS included in the PREMIER study (Primer Registro Mexicano de Isquemia Cerebral) which defined time from symptom onset to hospital arrival. The functional prognosis at 30 days and at 3, 6, and 12 months was evaluated using the modified Rankin Scale. RESULTS: Among 1096 patients with AIS, 61 (6%) arrived in <1 hour, 250 (23%) in <3 hours, and 464 (42%) in <6 hours. The factors associated with very early (<1 hour) arrival were family history of ischemic heart disease and personal history of migraines; in <3 hours: age 40-69 years, family history of hypertension, personal history of dyslipidaemia and ischaemic heart disease, and care in a private hospital; in <6 hours: migraine, previous stroke, ischaemic heart disease, care in a private hospital, and family history of hypertension. Delayed hospital arrival was associated with lacunar stroke and alcoholism. Only 2.4% of patients underwent thrombolysis. Regardless of whether or not thrombolysis was performed, arrival time in <3 hours was associated with lower mortality at 3 and 6 months, and with fewer in-hospital complications. CONCLUSIONS: A high percentage of patients had short hospital arrival times; however, less than 3% underwent thrombolysis. Although many factors were associated with early hospital arrival, it is a priority to identify in-hospital barriers to performing thrombolysis.


Subject(s)
Brain Ischemia/therapy , Stroke/therapy , Time-to-Treatment/statistics & numerical data , Adult , Aged , Aged, 80 and over , Brain Ischemia/mortality , Female , Humans , Male , Mexico , Middle Aged , Prognosis , Registries , Stroke/mortality , Thrombolytic Therapy , Treatment Outcome , Young Adult
4.
Eur J Neurol ; 20(1): 167-72, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22812600

ABSTRACT

BACKGROUND AND PURPOSE: To evaluate the incidence and predictors of ischaemic recurrent stroke and the adverse events of antithrombotic therapy in patients with first intra- or extracranial vertebral artery dissection (VAD) who were treated with aspirin or oral anticoagulation (OA). METHODS: A 21-year database of consecutive patients with confirmed diagnoses of VAD (n = 110, 63% men; mean age 37.9 ± 8.5 years) without intracerebral hemorrhage and who were treated with aspirin or OA were analyzed retrospectively. In all cases, the admission diagnosis was ischaemic stroke. Three groups were defined according to the site of the dissection: (i) extracranial, (ii) intracranial, and (iii) intra-/extracranial. Clinical follow-up was obtained by neurologic examination. Outcome measures were (i) recurrent ischaemic events (ischaemic stroke or transient ischaemic attack) and (ii) intra- and extracranial major bleeding. RESULTS: No difference in age, smoking, or hypertension was found between patients treated with OA (n = 49) and those treated with aspirin (n = 50). Extracranial artery dissection (49%) had preponderance over intracranial (27%) or intra-/extracranial (23%) location. During the follow-up, recurrent ischaemic events were rare (one case). There were no bleeding complications. The treatment that was used did not influence the functional outcome or recanalization. A good functional outcome (modified Rankin score ≤ 2) was observed in 82 patients. CONCLUSIONS: Although this was a non-randomized study, our data suggest that the frequency of recurrent ischaemic stroke in patients with intra- or extracranial VAD is low and most likely independent of the type of antithrombotic treatment.


Subject(s)
Anticoagulants/therapeutic use , Aspirin/therapeutic use , Carotid Artery, Internal, Dissection/drug therapy , Fibrinolytic Agents/therapeutic use , Vertebral Artery Dissection/drug therapy , Adult , Carotid Artery, Internal, Dissection/diagnosis , Databases, Factual/statistics & numerical data , Female , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Neurologic Examination , Physical Examination , Retrospective Studies , Statistics, Nonparametric , Tomography, X-Ray Computed , Treatment Outcome , Vertebral Artery Dissection/diagnosis
6.
Eur J Neurol ; 18(6): 819-25, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21143339

ABSTRACT

BACKGROUND AND PURPOSE: Although pregnancy and postpartum have long been associated with stroke, there is a dearth of information in Latino-American populations. The aim of this study was to describe the cerebrovascular complications occurring during pregnancy/postpartum and compare the characteristics amongst stroke types occurring in this period in Hispanic women. PATIENTS AND METHODS: We studied 240 women with cerebrovascular complications during pregnancy and the first 5 weeks postpartum, from our stroke registry. Patients were classified into three groups: cerebral venous thrombosis (CVT), ischaemic stroke (IS), and intracerebral hemorrhage (ICH). For each group, clinical data, timing of the event, and outcome were analyzed. RESULTS: Of the 240 women, 136 had CVT (56.7%), 64 IS (26.7%), and 40 ICH (16.6%). In 72 women (30%), the event occurred during pregnancy, in 153 (64%) during postpartum, and in 15 (6%) closely related to labor. CVT was more common in the first trimester of pregnancy and in the second and third weeks following delivery; whilst IS and ICH were seen mainly during pregnancy and the first 2 weeks following delivery. Pre-eclampsia/eclampsia was more common in patients with ICH (57.5%) and IS (36%) than in those with CVT (9.6%) (P < 0.001). An excellent recovery (modified Rankin Scale: 0-1) was observed amongst women with CVT (64%) and IS (50%) compared to ICH (32%), (P = 0.004). CONCLUSIONS: Pre-eclampsia/eclampsia is a frequent risk factor in patients with ICH and IS, but not in CVT. Stroke types clustered different within the pregnancy-postpartum period. A good prognosis is observed in patients with CVT.


Subject(s)
Cerebrovascular Disorders/diagnosis , Pregnancy Complications, Cardiovascular/diagnosis , Puerperal Disorders/diagnosis , Adolescent , Adult , Cerebrovascular Disorders/epidemiology , Cerebrovascular Disorders/ethnology , Comorbidity/trends , Female , Hispanic or Latino , Humans , Pregnancy , Pregnancy Complications, Cardiovascular/epidemiology , Pregnancy Complications, Cardiovascular/ethnology , Prognosis , Puerperal Disorders/epidemiology , Puerperal Disorders/ethnology , Registries , Stroke/diagnosis , Stroke/ethnology , Young Adult
7.
Rev Neurol ; 51(5): 289-94, 2010 Sep 01.
Article in Spanish | MEDLINE | ID: mdl-20669128

ABSTRACT

INTRODUCTION: Neuromyelitis optica (NMO) or Devic's disease is an autoimmune, inflammatory and demyelinating central nervous system disorder that affects mainly to optic nerve and spinal cord. Recent advances have substantially permitted to expand the knowledge about this entity. AIM: To present a clinical update on the current understanding of the nature, progression, diagnosis and treatment of NMO. DEVELOPMENT: Due to its demyelinating nature and its recurrent behavior in most cases, NMO was first considered a form of multiple sclerosis (MS). However, recent findings have led to the conclusion that NMO is a distinct disorder, presenting important immunopathological, clinical, prognostic and therapeutic differences from MS. Fundamental in the under-standing of the disease was the recent discovery of antibodies directed against aquaporin-4 (anti-AQP4, also known as NMO-IgG), which are present in the majority of NMO cases clinically defined, and in a minority of patients with MS. Despite the knowledge on its immunopathogenesis and advances in diagnosis, the treatment of NMO is still challenging. CONCLUSION: NMO is a demyelinating disease different from MS. Current diagnostic criteria have been enriched with the recent description of the humoral disorder underlying NMO. However, current treatment options for NMO are far from being ideal.


Subject(s)
Neuromyelitis Optica/immunology , Neuromyelitis Optica/pathology , Neuromyelitis Optica/physiopathology , Aquaporin 4/immunology , Autoantibodies/immunology , Demyelinating Diseases/diagnosis , Demyelinating Diseases/immunology , Demyelinating Diseases/physiopathology , Demyelinating Diseases/therapy , Diagnosis, Differential , Disease Progression , Humans , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Multiple Sclerosis/physiopathology , Neuromyelitis Optica/therapy , Prognosis
8.
Methods Find Exp Clin Pharmacol ; 32(5): 325-30, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20664823

ABSTRACT

Some neuroprotective agents have shown benefits in animal models, but disappointing results in humans. Citicoline is used in several countries as coadjuvant treatment in acute ischemic stroke (AIS) patients; however, there are no retrospective postmarketing surveillances on the experience of citicoline in Mexico. The aim of this study was to evaluate the correlation between citicoline exposure and functional outcome at discharge and at 30 and 90 days post-stroke, in a retrospective case-control design on systematic descriptive databases from three referral hospitals. Clinical records of 173 consecutively registered patients were analyzed, 86 of whom were treated with citicoline within the first 48 h after AIS and the remaining 87 were untreated, randomly selected controls matched for age (+/- 5 years), gender and NIHSS (+/- 1 point) at hospital admission. Pretreatment conditions were similar between groups. Compared with controls, exposure to citicoline was associated with a significantly lower 30-day mean and median modified Rankin score (in both, P < 0.05). After paired multivariate analyses (controlled for NIHSS, age, gender, hospital arrival in < 24 h, thrombolysis and comorbidities) citicoline was independently associated with a lower 90-day mortality risk (P = 0.047) and with fewer in-hospital complications (mainly infections and sepsis, P = 0.001). In this observational study, citicoline use was associated with a better functional status and lower rates of short-term mortality, possibly due to fewer in-hospital systemic complications. The putative benefits should be interpreted as clinical associations, since this is not a randomized, controlled clinical trial.


Subject(s)
Brain Ischemia/drug therapy , Cytidine Diphosphate Choline/therapeutic use , Neuroprotective Agents/therapeutic use , Product Surveillance, Postmarketing , Stroke/drug therapy , Acute Disease , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Male , Middle Aged , Retrospective Studies
10.
Dis Markers ; 27(5): 225-30, 2009.
Article in English | MEDLINE | ID: mdl-20037210

ABSTRACT

BACKGROUND: The association of the apolipoprotein (Apo E) -epsilon4 allele to neurodegenerative diseases such as Parkinson's disease (PD) has been analyzed in several studies. This association has been identified by amyloid deposits and neurofibrillary tangles in the brains of patients with neurodegenerative diseases. METHOD: In this study the possible relationship between Apo E alleles and PD patients was analyzed in 105 patients with PD and 107 healthy controls from a Mexican population. RESULTS: Allele analysis in PD vs. controls was: epsilon2 in 6% and 2.3%, respectively; epsilon3 in 73% and 88.3%; and epsilon4} in 21% and 9.4%. The epsilon3 allele showed a protective risk effect with an Odds ratio (OR) of 0.36 (95%CI 0.20-0.61) and p < 0.05; contrary results were observed for the epsilon4 allele, which showed an increased risk for PD, with an OR of 2.57(95% CI 1.42-4.79) and p < 0.05. Upon multivariate analysis showed PD risk was evident in patients who were carriers of the genotype epsilon3/epsilon4; age group (fifty or more years) and had exposure to pesticides and solvents (p < 0.05). CONCLUSIONS: The epsilon3/epsilon3}; epsilon3/epsilon4 genotypes of the Apo E, were positively associated with sporadic PD.


Subject(s)
Apolipoproteins E/genetics , Parkinson Disease/genetics , Adult , Alleles , Base Sequence , Case-Control Studies , DNA Primers , Female , Genetic Predisposition to Disease , Genotype , Humans , Male , Mexico , Middle Aged , Multivariate Analysis
11.
Rev Neurol ; 44(1): 15-7, 2007.
Article in Spanish | MEDLINE | ID: mdl-17199224

ABSTRACT

INTRODUCTION: Parkinson disease (PD) is the second most common neurodegenerative disease of adult onset. Is a progressive movement disorder including tremor, bradykinesia, rigidity and postural instability, with an age onset between 43 and 66 years. Histopathologically, is characterized by a severe loss of dopaminergic neurons in the substantia nigra and inclusions consisting of insoluble protein aggregates called Lewy bodies, this are comprised in part of alpha-synuclein. The etiology of PD is still not fully understood, but genetic analyses, epidemiologic studies and experimental models of PD are providing important new insights into the pathogenesis of PD. AIM: To determine allelic and genotypic frequencies of polymorphism IVS4+66A-G in the alpha-synuclein gene and to demonstrate its association with PD in northwest Mexican population. SUBJECTS AND METHODS: Genomic desoxyribonucleic acid (DNA) from 51 PD patients and 121 persons without PD were achieved by polymerase chain reaction and analyzed the allelic and genotypic distribution in IVS4+66A-G polymorphism of alpha-synuclein gene. RESULTS: The genotypic frequency of IVS4+66AA was 43.1% in PD patients and 38.8% in control group; IVS4+66GG was 2% in PD patients and 4.1% in control group, whereas 54.9% in PD patients and 57.1% in control group were heterozygous. Statistical differences were not observed between groups (p<0.05). CONCLUSIONS: Association was not observed between the IVS4+66A-G polymorphism and PD.


Subject(s)
Parkinson Disease/genetics , Polymorphism, Genetic , alpha-Synuclein/genetics , Adult , Aged , Aged, 80 and over , Case-Control Studies , Humans , Mexico , Middle Aged
12.
Rev. neurol. (Ed. impr.) ; 44(1): 15-17, 1 ene., 2007.
Article in Es | IBECS | ID: ibc-053078

ABSTRACT

Introducción. La enfermedad de Parkinson (EP) es la segunda enfermedad neurodegenerativa más común en la edad adulta. Es un trastorno de movimientos progresivos que incluye una tétrada caracterizada por temblor en reposo, bradicinesia, rigidez y alteraciones de los reflejos posturales con una edad de inicio de 43 a 66 años. Histopatológicamente, se caracteriza por una pérdida grave de neuronas dopaminérgicas en la sustancia negra e inclusiones que consisten en agregados insolubles de proteínas llamados cuerpos de Lewy, compuestas en parte por alfa-sinucleína. La etiología de la EP no es clara, pero análisis genéticos, epidemiológicos y modelos experimentales proveen importantes hallazgos en la patogénesis de la EP. Objetivo. Determinar las frecuencias alélicas y genotípicas del polimorfismo IVS4+66A-G en el gen alfa-sinucleína y evidenciar su posible asociación con la EP en población del noroccidente de México. Sujetos y métodos. Se analizó el ADN genómico de 51 pacientes con EP y 121 personas sin EP mediante la reacción en cadena de la polimerasa para determinar las frecuencias alélicas y genotípicas del polimorfismo IVS4+66A-G. Resultados. La frecuencia genotípica de IVS4+66AA fue del 43,1% en el grupo de pacientes y del 38,8% en el grupo control, y de IVS4+66GG, del 2% en pacientes y del 4,1% en controles. La frecuencia de heterocigotos observada fue del 54,9% en pacientes y del 57,1% en controles. No se observó diferencia significativa entre los grupos (p < 0,05). Conclusión. No existe evidencia de asociación entre el polimorfismo IVS4+66A-G y la EP


Introduction. Parkinson’s disease (PD) is the second most common neurodegenerative disease of adult onset. Is a progressive movement disorder including tremor, bradykinesia, rigidity and postural instability, with an age onset between 43 and 66 years. Histopathologically, is characterized by a severe loss of dopaminergic neurons in the substantia nigra and inclusions consisting of insoluble protein aggregates called Lewy bodies, this are comprised in part of alpha-synuclein. The etiology of PD is still not fully understood, but genetic analyses, epidemiologic studies and experimental models of PD are providing important new insights into the pathogenesis of PD. Aim. To determine allelic and genotypic frequencies of polymorphism IVS4+66A-G in the alpha-synuclein gene and to demonstrate its association with PD in northwest Mexican population. Subjects and methods. Genomic DNA from 51 PD patients and 121 persons without PD were achieved by polymerase chain reaction and analyzed the allelic and genotypic distribution in IVS4+66A-G polymorphism of alpha-synuclein gene. Results. The genotypic frequency of IVS4+66AA was 43.1% in PD patients and 38.8% in control group; IVS4+66GG was 2% in PD patients and 4.1% in control group, whereas 54.9% in PD patients and 57.1% in control group were heterozygous. Statistical differences were not observed between groups (p < 0.05). Conclusions. Association was not observed between the IVS4+66A-G polymorphism and PD


Subject(s)
Male , Female , Adult , Middle Aged , Humans , Parkinson Disease/genetics , Parkinson Disease/pathology , Parkinson Disease/etiology , Mexico/epidemiology , Genotype , Polymorphism, Genetic
13.
Acta Neurochir (Wien) ; 148(9): 1011-4, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16614804

ABSTRACT

Idiopathic hypertrophic cranial pachymeningitis is a very infrequent disorder. Adequate management is still a matter of debate. We describe the use of low-dose pulse methotrexate in treating a 63-year-old woman with idiopathic hypertrophic cranial pachymeningitis. A weekly scheme with subcutaneous methotrexate was tried. Clinical improvement occurred in one week. Total remission of the clinical and neuro-imaging abnormalities was evident 6 months later, with minimal side effects. The patient is in complete remission after one year of follow-up without treatment. Hence, low-dose weekly subcutaneous methotrexate may be safe and effective in inducing complete and sustained remission of this condition. The experience with subcutaneous methotrexate to treat this entity has never been reported.


Subject(s)
Dura Mater/drug effects , Dura Mater/pathology , Hypertrophy/drug therapy , Meningitis/drug therapy , Methotrexate/administration & dosage , Cerebellar Diseases/etiology , Cerebellar Diseases/physiopathology , Cranial Nerve Diseases/etiology , Cranial Nerve Diseases/pathology , Cranial Nerve Diseases/physiopathology , Dose-Response Relationship, Drug , Drug Administration Schedule , Dura Mater/physiopathology , Female , Headache Disorders/etiology , Headache Disorders/physiopathology , Humans , Hypertrophy/etiology , Hypertrophy/physiopathology , Immunosuppressive Agents/administration & dosage , Magnetic Resonance Imaging , Meningitis/etiology , Meningitis/physiopathology , Middle Aged , Remission Induction , Treatment Outcome
14.
Rev. neurol. (Ed. impr.) ; 41(9): 534-537, nov. 2005. ilus
Article in Spanish | IBECS | ID: ibc-128273

ABSTRACT

Introducción. La esclerodermia lineal en ‘golpe de sable’, mejor conocida como esclerodermia lineal en coup de sabre (ELCS), es una enfermedad rara de causa incierta, caracterizada por atrofia focal progresiva craneofacial y, en parte, es diferente al síndrome de Parry-Romberg (SPR). Casos clínicos. Comunicamos tres pacientes con ELCS (2 mujeres y 1 hombre, con un promedio de edad de 40 años). Las manifestaciones neurológicas principales fueron cefalea y crisis convulsivas. Los alteraciones radiológicas, aunque diversas, fueron todas ipsilaterales al ‘golpe de sable’. En una paciente sometida a biopsia se obtuvo evidencia histopatológica de gliosis e infiltrado inflamatorio mixto perivascular. Destacamos en otro paciente la afectación cerebrovascular, dado el hallazgo de un infarto cerebeloso antiguo subclínico y oclusión de la arteria cerebelosa superior en ausencia de otra posible causa. Conclusiones. La ELCS, cuando afecta al sistema nervioso central es heterogénea en su presentación clínica y radiológica. Los estudios de imagen durante el control clínico y los hallazgos histopatológicos apoyan un proceso inflamatorio focal que puede ser progresivo. La afectación arterial se debe probablemente a una vasculopatía inflamatoria no ateroesclerosa, oclusiva y crónica (AU)


Introduction. ‘Sword stroke’ linear scleroderma, which is better known as linear scleroderma en coup de sabre (LSCS), is a rare disease with an uncertain causation that is characterised by progressive craniofacial focal atrophy and is, at least in part, different from Parry-Romberg syndrome (PRS). Case reports. Here, we report on the cases of 3 patients with LSCS (2 females and 1 male, with a mean age of 40 years). The main neurological symptoms were headache and seizures. Although different alterations were observed in the X-ray images, they were all ipsilateral to the coup de sabre. Histopathological evidence for gliosis and mixed perivascular inflammatory infiltrate was found in the study of a biopsy specimen taken from one female. Cerebrovascular involvement was seen in another patient, as highlighted by the observation of an earlier subclinical cerebellar infarct and occlusion of the superior cerebellar artery in the absence of any other possible causation. Conclusions. When it affects the central nervous system, the clinical and radiological presentation of LSCS is heterogeneous. Both the imaging studies carried out during the clinical control and the histopathological findings suggest a focal inflammatory process that can be progressive. The arterial involvement is probably due to a non-atherosclerotic, occlusive and chronic inflammatory disease of the peripheral vessels (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Scleroderma, Localized/diagnosis , Facial Hemiatrophy/diagnosis , Sclerosis/physiopathology , Magnetic Resonance Spectroscopy , Hemianopsia/diagnosis
15.
Rev Neurol ; 41(9): 534-7, 2005.
Article in Spanish | MEDLINE | ID: mdl-16254860

ABSTRACT

INTRODUCTION: 'Sword stroke' linear scleroderma, which is better known as linear scleroderma en coup de sabre (LSCS), is a rare disease with an uncertain causation that is characterised by progressive craniofacial focal atrophy and is, at least in part, different from Parry-Romberg syndrome (PRS). CASE REPORTS: Here, we report on the cases of 3 patients with LSCS (2 females and 1 male, with a mean age of 40 years). The main neurological symptoms were headache and seizures. Although different alterations were observed in the X-ray images, they were all ipsilateral to the coup de sabre. Histopathological evidence for gliosis and mixed perivascular inflammatory infiltrate was found in the study of a biopsy specimen taken from one female. Cerebrovascular involvement was seen in another patient, as highlighted by the observation of an earlier subclinical cerebellar infarct and occlusion of the superior cerebellar artery in the absence of any other possible causation. CONCLUSIONS: When it affects the central nervous system, the clinical and radiological presentation of LSCS is heterogeneous. Both the imaging studies carried out during the clinical control and the histopathological findings suggest a focal inflammatory process that can be progressive. The arterial involvement is probably due to a non-atherosclerotic, occlusive and chronic inflammatory disease of the peripheral vessels.


Subject(s)
Scleroderma, Localized , Adult , Brain/anatomy & histology , Brain/pathology , Female , Humans , Inflammation/pathology , Inflammation/physiopathology , Male , Middle Aged , Scleroderma, Localized/diagnosis , Scleroderma, Localized/pathology , Scleroderma, Localized/physiopathology
16.
Rev Neurol ; 40(11): 656-60, 2005.
Article in Spanish | MEDLINE | ID: mdl-15948067

ABSTRACT

INTRODUCTION: Intracerebral haemorrhage (ICH) has received little attention in studies in Mexico. Isolated reports talk of high frequency, its importance as a disorder among young people, its being mainly located in the lobar regions and a high rate of recurrence. AIMS: The objective of this study was to characterise the clinical, radiological, therapeutic and prognostic spectrum of ICH in a general hospital in the central-western region of Mexico. PATIENTS AND METHODS: The study involved 270 consecutive patients over the age of 15 years with spontaneous ICH who were hospitalised in the Neurology and Neurosurgical Service in the Antiguo Hospital Civil de Guadalajara between the years 2000 and 2002. Their clinical history and progression was known at least on discharge from the hospital. RESULTS: The mean age was 63 years (12% under 40 years old) with no predominance according to gender (53% males). Arterial hypertension was the main risk factor in 69%, followed by obesity in 38%. There were no differences in the Glasgow administered on admission in three pre-established subgroups. The ICH was ganglionic in 64% of cases and lobar in 24%. Arterial hypertension was the principal cause of ICH in 76%. Ventricular aperture was noted in 53%. All the patients were treated in a general ward. Mortality in the acute phase occurred in 49%, although a poor progression was observed in 83%. Overall recurrence was 13%. Outpatient follow-up was poor. CONCLUSIONS: ICH shares most of the features reported in Anglo-Saxon series including aetiology and location. In our population, mortality and recurrence are high with important sequelae. The high frequency of ICH (40%) may represent a bias in the selection of hospitals.


Subject(s)
Cerebral Hemorrhage/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/etiology , Cerebral Hemorrhage/therapy , Female , Hospital Mortality , Hospitals, General/statistics & numerical data , Humans , Hypertension/complications , Length of Stay/statistics & numerical data , Male , Mexico/epidemiology , Middle Aged , Obesity/complications , Prognosis , Radiography , Recurrence , Retrospective Studies , Rupture, Spontaneous , Treatment Outcome
17.
Rev. neurol. (Ed. impr.) ; 40(11): 656-660, 1 jun., 2005. tab
Article in Spanish | IBECS | ID: ibc-128842

ABSTRACT

Introducción. La hemorragia intracerebral (HIC) se ha estudiado escasamente en México. Algunos comunicados aislados señalan una elevada frecuencia, importante afectación en jóvenes, mayor localización lobar y alta recurrencia. Objetivos. Caracterizar el espectro clínico, radiológico, terapéutico y pronóstico de la HIC en un hospital general de la región centro-occidente de México. Pacientes y métodos. Se incluyeron 270 pacientes consecutivos mayores de 15 años con HIC espontánea ingresados en el Servicio de Neurología y Neurocirugía del Antiguo Hospital Civil de Guadalajara, entre los años 2000 y 2002. Todos tenían historia clínica y una evolución conocida, al menos, hasta el alta hospitalaria. Resultados. La edad promedio fue de 63 años (12% menores de 40 años) sin predominio de sexo (53% hombres). La hipertensión arterial fue el principal factor de riesgo (69%), seguida de la obesidad (38%). No hubo diferencia en el Glasgow al ingreso en tres subgrupos preestablecidos. La localización de la HIC fue ganglionar en el 64% y lobar en el 24%. La hipertensión arterial fue la principal causa de HIC en el 76%. La apertura ventricular se consignó en un 53%. Todos los pacientes se trataron en la sala general. La mortalidad en fase aguda se dio en el 49%, aunque se consignó una mala evolución en el 83%. La recurrencia global fue de 13%. El seguimiento por consulta externa es pobre. Conclusiones. La HIC comparte la mayoría de las características comunicadas en series anglosajonas con inclusión de etiología y localización. En nuestra población, la mortalidad y la recurrencia son altas, con secuelas importantes. La elevada frecuencia de HIC (40%) puede representar un sesgo de selección hospitalaria (AU)


Introduction. Intracerebral haemorrhage (ICH) has received little attention in studies in Mexico. Isolated reports talk of high frequency, its importance as a disorder among young people, its being mainly located in the lobar regions and a high rate of recurrence. Aims. The objective of this study was to characterise the clinical, radiological, therapeutic and prognostic spectrum of ICH in a general hospital in the central-western region of Mexico. Patients and methods. The study involved 270 consecutive patients over the age of 15 years with spontaneous ICH who were hospitalised in the Neurology and Neurosurgical Service in the Antiguo Hospital Civil de Guadalajara between the years 2000 and 2002. Their clinical history and progression was known at least on discharge from the hospital. Results. The mean age was 63 years (12% under 40 years old) with no predominance according to gender (53% males). Arterial hypertension was the main risk factor in 69%, followed by obesity in 38%. There were no differences in the Glasgow administered on admission in three pre-established subgroups. The ICH was ganglionic in 64% of cases and lobar in 24%. Arterial hypertension was the principal cause of ICH in 76%. Ventricular aperture was noted in 53%. All the patients were treated in a general ward. Mortality in the acute phase occurred in 49%, although a poor progression was observed in 83%. Overall recurrence was 13%. Outpatient follow-up was poor. Conclusions. ICH shares most of the features reported in Anglo-Saxon series including aetiology and location. In our population, mortality and recurrence are high with important sequelae. The high frequency of ICH (40%) may represent a bias in the selection of hospitals (AU)


Subject(s)
Humans , Cerebral Hemorrhage/epidemiology , Cerebrovascular Disorders/epidemiology , Cerebral Infarction/epidemiology , Subarachnoid Hemorrhage/epidemiology , Mexico/epidemiology , Neurologic Examination/methods , Risk Factors
20.
Clin Appl Thromb Hemost ; 8(2): 169-77, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12121059

ABSTRACT

Acetylsalicylic acid inhibits thromboxane A2 production and reduces the risk of vascular occlusive events by 20% to 25%. Ticlopidine inhibits ADP-dependent platelet aggregation and reduces the same risk by 30% to 35%, but produces some adverse effects. Clopidogrel is a ticlopidin-related antiplatelet drug, with the same mechanism of action; it reduces the expression of the glycoprotein IIb/IIIa, the fibrinogen receptor on the platelet surface. Clopidogrel has the same clinical efficacy of ticlopidin and has a decreased incidence of adverse effects. The effect of one daily dose of 75 mg of clopidogrel on platelet function in 90 subjects was evaluated; 41 with coronary artery disease and 49 with cerebral vascular disease. Before treatment and after 6 and 12 weeks, bleeding time and fibrinogen plasma concentration were also evaluated. There was a reduction in 5-microM ADP-induced platelet aggregation of 38%+/-27% at 6 weeks and 44%+/-29% at 12 weeks in patients with coronary artery disease; 35%+/-41%, 29%+/-59% in the cerebral vascular disease group; and 36%+/-36% and 35%+/-49% in the total group. Reduction of 20 microg/mL collagen-induced platelet aggregation was not significant in any group. Plasma fibrinogen levels did not vary during treatment. Bleeding time was significantly prolonged in all studied groups. There were no hemorrhagic complications; only digestive discomfort in less than 3% of patients. Clopidogrel efficiently reduces ADP-induced platelet aggregation and prolongs bleeding time and is a safe and efficacious antiplatelet drug.


Subject(s)
Clopidol/administration & dosage , Coronary Artery Disease/drug therapy , Fibrinogen/drug effects , Intracranial Arteriosclerosis/drug therapy , Platelet Aggregation/drug effects , Adenosine Diphosphate/pharmacology , Adult , Aged , Aged, 80 and over , Clopidol/pharmacology , Clopidol/toxicity , Collagen/pharmacology , Coronary Artery Disease/blood , Coronary Artery Disease/etiology , Family Health , Humans , Intracranial Arteriosclerosis/blood , Intracranial Arteriosclerosis/etiology , Male , Middle Aged , Platelet Function Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...